Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers

119Citations
Citations of this article
84Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

INTRODUCTION: Bevacizumab improves survival in patients with advanced non-small-cell lung cancer (NSCLC). This phase II clinical trial assessed the effects of the addition of bevacizumab to neoadjuvant chemotherapy in resectable nonsquamous NSCLC. METHODS: Patients with resectable stage IB-IIIA nonsquamous NSCLC were treated with bevacizumab followed by imaging 2 weeks later to assess single-agent effect. After this they received two cycles of bevacizumab with four cycles of cisplatin and docetaxel followed by surgical resection. Resected patients were eligible for adjuvant bevacizumab. The primary endpoint was the rate of pathological downstaging (decrease from pretreatment clinical stage to post-treatment pathological stage). Secondary endpoints included overall survival, safety, and radiologic response. RESULTS: Fifty patients were enrolled. Thirty-four (68%) were clinical stage IIIA. All three doses of neoadjuvant bevacizumab were delivered to 40 of 50 patients. Six patients (12%) discontinued because of bevacizumab-related adverse events. The rate of downstaging (38%), response to chemotherapy (45%), and perioperative complications (12%) were comparable with historical data. No partial responses were observed to single-agent bevacizumab, but 18% of the patients developed new intratumoral cavitation, with a trend toward improved pathologic response (57% versus 21%; p = 0.07). A major pathologic response (≥90% treatment effect) was associated with survival at 3 years (100% versus 49%; p = 0.01). No patients with KRAS-mutant NSCLC (0 of 10) had a pathologic response as compared with 11 of 31 with wild-type KRAS. CONCLUSION: Although preoperative bevacizumab plus chemotherapy was feasible, it did not improve downstaging in unselected patients. New cavitation after single-agent bevacizumab is a potential biomarker. Alternative strategies are needed for KRAS-mutant tumors. © 2013 by the International Association for the Study of Lung Cancer.

References Powered by Scopus

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

23412Citations
N/AReaders
Get full text

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

5505Citations
N/AReaders
Get full text

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

3039Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Neoadjuvant PD-1 blockade in resectable lung cancer

1513Citations
N/AReaders
Get full text

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint

482Citations
N/AReaders
Get full text

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

461Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chaft, J. E., Rusch, V., Ginsberg, M. S., Paik, P. K., Finley, D. J., Kris, M. G., … Rizvi, N. A. (2013). Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. Journal of Thoracic Oncology, 8(8), 1084–1090. https://doi.org/10.1097/JTO.0b013e31829923ec

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 27

60%

Researcher 13

29%

Professor / Associate Prof. 3

7%

Lecturer / Post doc 2

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 40

82%

Agricultural and Biological Sciences 4

8%

Biochemistry, Genetics and Molecular Bi... 4

8%

Pharmacology, Toxicology and Pharmaceut... 1

2%

Save time finding and organizing research with Mendeley

Sign up for free